What is the Finnish SUPER study?
The Finnish SUPER study on genetic mechanisms of psychotic disorders is a part of the international Stanley Global Neuropsychiatric Genomics Initiative. The objective of the study is to better understand the genetic and biological background of psychotic disorders in order to provide more accurate information for the development of new therapeutic interventions.
Finland is the European pilot country of the Stanley Global Initiative. The study was commenced with a pilot study in three regions in the fall of 2015. The national study was launched in early 2016 and will continue for three years. As of January 2018, over 7,000 consents have been collected.
In Finland the aim is to collect a minimum of 10,000 genetic samples from psychosis patients.
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, is leading the study in collaboration with the National Institute for Health and Welfare (THL). FIMM will coordinate the sample collection, and THL is responsible for sample logistics. Five university hospital districts will be involved in the sample collection.
As part of the Stanley Global Neuropsychiatric Genomics Initiative, similar studies will be undertaken in Mexico, a Sub Saharan country and East Asian countries (to be announced later). The Initiative, including the Finnish SUPER study, is funded by the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard.
The director of the Finnish study arm
Professor Aarno Palotie (firstname.lastname@example.org)
National Study Coordinators
Markku Lähteenvuo (email@example.com)
Kaisla Joutsenniemi (firstname.lastname@example.org)
Risto Kajanne (email@example.com)